NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over 1 billion; including 142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe - Obicetrapib is a next-generation oral, low-dose and once-daily CETP inhibitor for which promising safety and strong LDL-lowering efficacy has been observed in patients with dyslipidemia through Phase 2b MIAMI and FLORENCE, Italy and NAARDEN, Netherlands, June 29, 2022 /PRNewswire/ NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international pharmaceutical company, today announced an exclusive license agreement for the commercialization of obicetrapib, if approved, in Europe, eithe
- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over 1 billion; including 142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net product sales in Europe - Obicetrapib is a next-generation oral, low-dose and once-daily CETP inhibitor for which promising safety and strong LDL-lowering efficacy has been observed in patients with dyslipidemia through Phase 2b MIAMI and FLORENCE, Italy and NAARDEN, Netherlands, June 29, 2022 /PRNewswire/ NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international pharmaceutical company, today announced an exclusive license agreement for the commercialization of obicetrapib, if approved, in Europe, eithe
New post-hoc data accepted as late breaking abstracts at the 90th European Atherosclerosis Society (EAS) Congress and 2022 National Lipid Association (NLA) Scientific Sessions NewAmsterdam Pharma
NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases, today announced the publication of a new meta-analysis